NRIX - CIK 0001549595
Nurix Therapeutics, Inc. (NRIX) reported net income of -$264.46M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$264.46M | -36.6% |
| FY 2024 | -$193.57M | -34.5% |
| FY 2023 | -$143.95M | +20.2% |
| FY 2022 | -$180.36M | -53.9% |
| FY 2021 | -$117.19M | -171.0% |
| FY 2020 | -$43.24M | -99.3% |
| FY 2019 | -$21.70M | - |
Nurix Therapeutics, Inc. (NRIX) reported net income of -$264.46M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2019 and fiscal 2025, Nurix Therapeutics, Inc.'s net income declined from -$21.70M to -$264.46M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.